Stay updated with breaking news from Johan Dighed. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investegate announcements from Karolinska Development AB (pub, Karolinska Development’s portfolio company Modus Therapeutics initiates Phase 1b trial of its drug candidate sevuparin
STOCKHOLM SWEDEN - December 1, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Modus Therapeutics has dosed the first subject in a phase 1b study of
STOCKHOLM, SWEDEN - November 3, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company Umecrine Cognition will present new scientific results showing that the
STOCKHOLM, SWEDEN - October 27, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company Dilafor, a drug development company focusing on the development of tafoxiparin
STOCKHOLM, SWEDEN - October 19, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company Umecrine Cognition has entered a collaboration with Professor Trevor